What contraceptive options are suitable for a woman with migraine without aura?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Contraceptive Options for Women with Migraine Without Aura

Women with migraine without aura can safely use any contraceptive method, including combined hormonal contraceptives, as they do not have an increased risk of stroke compared to women with migraine with aura.

Safe Contraceptive Options

Combined Hormonal Contraceptives (CHCs)

  • Combined oral contraceptives (COCs), vaginal rings, and patches are all appropriate options 1
  • Low-dose formulations (containing ethinyl estradiol 35 μg or less) are preferred 1
  • Extended or continuous regimens (24/4 rather than 21/7) may be beneficial for reducing menstrual migraine severity 2

Progestin-Only Methods

  • All progestin-only methods are safe and appropriate:
    • Progestin-only pills
    • Levonorgestrel intrauterine device (IUD) - particularly beneficial for menstrual migraine 3
    • Etonogestrel implant (Nexplanon)
    • Depot medroxyprogesterone acetate injections

Non-Hormonal Methods

  • Copper IUD
  • Barrier methods (condoms, diaphragms, caps)
  • Fertility awareness methods

Benefits of Hormonal Contraception for Migraine Without Aura

  • Hormonal contraceptives, particularly extended regimens, can help manage menstrual migraine by stabilizing estrogen levels 4
  • The 24/4 COC regimen (24 active pills + 4 placebo pills) has been shown to significantly reduce the intensity and duration of menstrual migraine compared to the traditional 21/7 regimen 2
  • The levonorgestrel IUD is recommended by the American College of Obstetricians and Gynecologists as a preferred continuous progestogen option for menstrual migraine prevention 3

Important Monitoring Considerations

  • Regular follow-up every 6-12 months to monitor:

    • Changes in migraine pattern
    • Development of aura symptoms (which would necessitate discontinuation of CHCs)
    • Cardiovascular risk factors
    • Treatment effectiveness using headache calendars 3
  • Blood pressure should be monitored at baseline and during follow-up visits 1

Key Distinctions and Warnings

  • Important distinction: Migraine WITH aura is a contraindication to combined hormonal contraceptives due to significantly increased stroke risk 1, 3
  • Monitor for development of aura symptoms, which would require discontinuation of CHCs
  • Additional risk factors that would contraindicate CHC use include:
    • Age ≥35 years and smoking
    • Uncontrolled hypertension
    • Thrombophilia or history of thromboembolism
    • Complicated valvular heart disease 1

Algorithm for Contraceptive Selection in Migraine Without Aura

  1. First-line options:

    • Low-dose combined hormonal contraceptives (≤35 μg ethinyl estradiol) if no other contraindications exist
    • Consider extended or continuous regimens (24/4) for better migraine control
  2. If menstrual migraine is severe or patient prefers non-estrogen methods:

    • Levonorgestrel IUD
    • Other progestin-only methods
  3. If hormonal methods are contraindicated or not desired:

    • Copper IUD
    • Barrier methods
  4. Immediately discontinue CHCs and switch to non-estrogen methods if:

    • Aura symptoms develop
    • New cardiovascular risk factors emerge
    • Migraine frequency or severity significantly worsens

By following these guidelines, women with migraine without aura can safely use contraceptive methods that may also help manage their migraine symptoms.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Menstrual Migraine Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Migraine, menopause and hormone replacement therapy.

Post reproductive health, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.